Approximately 40-75% of drugs in today’s development pipeline have either poor bioavailability, nonlinear pharmacokinetics, or a significant food effect on bioavailability. Drugs that suffer from poor bioavailability are doomed to fail – it’s just a matter of time.
Watch this webinar to hear from a formulation scientist who knows how to give your compound a better chance to succeed. You’ll learn about the Developability Classification System (DCS), which can accurately predict challenges with oral bioavailability 90% of the time. See how using this tool in early development can help create a strategy for in vivo studies to guide decisions and maximize success.
Darren Matthews, BS, PhD
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.